Company: SRPT
Filing Date: 2025-02-28
Form Type: 10-K
Source: 0000950170-25-029973
Chunk: 123

Company: Sarepta Therapeutics, Inc.
Filing Date: 2025-02-28
Form: 10-K
Item: Item 15
Chunk 123
---
 Nationwide Children's Hospitaland Sarepta Therapeutics, Inc.
     
    10-Q
     
    001-14895
     
    10.3
     
    8/2/23

     10.65^
     
    Second Amendment, dated July 11, 2023,to the Exclusive License Agreement betweenResearch Institute at Nationwide Children's Hospitaland Sarepta Therapeutics, Inc.
     
    10-Q
     
    001-14895
     
    10.4
     
    8/2/23

     10.66
     
    Credit Agreement, dated February 13, 2025, among Sarepta Therapeutics, Inc., Sarepta Therapeutics 
     
    8-K
     
    001-14895
     
    10.1
     
    2/14/25

-90-

    Investments, Inc., JPMorgan Chase Bank, N.A., as administrative agent, and the lenders party thereto

     10.67^
     
    Exclusive License and Collaboration Agreement, dated November 25, 2024, between Sarepta Therapeutics, Inc. and Arrowhead Pharmaceuticals, Inc.

    X

     19.1
     
    Sarepta Therapeutics, Inc. Insider Trading Policy

    X

     21.1
     
    Subsidiaries of the Registrant.

    X

     23.1
     
    Consent of Independent Registered Public Accounting Firm.

    X

     24.1
     
    Power of Attorney (contained on signature page).

    X

     31.1
     
    Certification of the Company’s President and Chief Executive Officer, Douglas S. Ingram, pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

    X

     31.2
     
    Certification of the Company’s Executive Vice President, Chief Financial Officer, Ian Estepan, pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

    X

     32.1**
     
    Certification of the Company’s President and Chief Executive Officer, Douglas S. Ingram, pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

    X

     32.2**
     
    Certification of the Company’s Executive Vice President